Keywords
How to Cite
Abstract
Aims were to compare the characteristics of hormonal and metabolic status, a set of proinflammatory and antiinflammatory markers, as well as factors associated with DNA damage/ genome integrity in endometrial cancer (EC) patients, divided on the basis of the contemporary classification that distinguishes four molecular-biological types of this tumor.
Materials and methods: The study involved material from untreated EC patients, the number of which varied depending on the method used. The average age of patients was close to 60 years and about 90% of them were in postmenopausal period. In the course of evaluation of pro-inflammatory and antiinflammatory factors (levels of cytokines IL-6 and TNF, myo-kine myostatin and adipokine prefilin / Pref-1 /, the ratio of neutrophils/lymphocytes in the blood), an enzyme immunoassay and hematological analysis were used, while the study of the expression of lipoxygenases’ mRNA (“pro-inflammatory” alox5 and “anti-inflammatory” alox15) in omental adipose tissue was based on real-time PCR methodology. Besides, the comet tail moment and % of DNA in the tail of comets of mononuclear cells, the level of 8-hydroxy-2-deoxyguanosine in circulation and the telomere length of mononuclear cells were, respectively, measured as an indicators of DNA damage or genome integrity.
Results and conclusions: According to the data obtained, the differences between EC patients are determined not only by the propensity for overweight or lack of it, but also by belonging of the individual case to one or another molecular-biological type established on the basis of genetic and immu-nohistochemical analysis of the tumor tissue. Altogether this may indicate certain specificity of stimuluses leading to the development of particular endometrial cancer variant.
References
Берлев И.В., Берштейн Л.М., Урманчеева А.Ф. (ред.) Рак эндометрия. - Спб, Эко-Вектор, 2017. - 264 с.
Sheikh M.A., Althouse A.D., Freese K.E. et al. USA endometrial cancer projections to 2030: should we be concerned? // Future oncology. - 2014. - Vol. 10(16). - P. 2561-2568.
Коломиец Л.А., Бочкарева Н.В., Чернышева А.Л. Рак эндометрия и метаболический синдром. - Томск: Иван Федоров, 2010. - 228 с.
Hjartaker A., Langseth H., Weiderpass E. Obesity and diabetes epidemics: cancer repercussions // Adv. Exp. Med. Biol. - 2008. - Vol. 630. - P. 72-93.
Berstein L.M., Poroshina T.E., Turkevich E.A. et al. Features of endometrial cancer in patients with ‘metabolically healthy' versus ‘standard' obesity: the decreasing frequency of metabolically healthy obesity // Future Sci. OA. - 2015. - Vol. 1(4). - FSO68. - 10.4155/ fso.15.68. DOI: 10.4155/fso.15.68
Berthelsen H.G., Svane H.A. Cancer of the endometrium and hyperestrinism; two different modes of origin of endometrial cancer // Dan Med Bull. - 1956. - Vol. 3(8). - P. 236-239.
Бохман Я.В. Рак тела матки. - Кишинев: Штиинца, 1972. - 202 с.
Sherman M.E. Theories of endometrial carcinogenesis: a multidisciplinary approach // Mod Pathol. - 2000. - Vol. 13(3). - P. 295-308.
Berstein L.M., Berlev I.V., Baltrukova A.N. Endometrial cancer evolution: new molecular-biologic types and hormonal-metabolic shifts // Future Oncol. - 2017. - Vol. 13(28). -P. 2593-2605.
Cancer Genome Atlas Research Network, Kandoth C., Schultz N., Cherniack A.D. et al. Integrated genomic characterization of endometrial carcinoma // Nature. - 2013. -Vol. 497(7447). - P. 67-73. - 10.1038/ Nature12113. DOI: 10.1038/nature12113
McAlpine J.N., Temkin S.M., Mackay H.J. Endometrial Cancer: Not your grandmother's Cancer // Cancer. - 2016. - Vol. 122(18). - P. 2787-2798. - 10.1002/ cncr.30094. DOI: 10.1002/cncr.30094
Suarez A.A., Felix A.S., Cohn D.E. Bokhman Redux: Endometrial cancer "types" in the 21st century // Gynecol. Oncol. - 2017. - Vol. 144(2). - P. 243-249.
Talhouk A., Hoang L.N., McConechy M.K. et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Prognostic information to guide treatment // Gynecol. Oncol. - 2016. - Vol. 143(1). - P. 46-53.
Talhouk A., McConechy M.K., Leung S. et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial Cancer // Cancer. - 2017. - Vol. 123(5). - P. 802-813. - DOI: 10.1002/cncr.30496
Берштейн Л.М., Порошина Т.Е., Васильев Д.А. и др. Сравнительные особенности состояния углеводного обмена и массы тела при различных молекулярнобиологических типах рака эндометрия // Вопр. Онкол. - 2018. - Т. 64 (3). - С. 394-398.
Dossus L., Lukanova A., Rinaldi S. et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-a factor analysis // Am. J. Epidemiol. - 2013. - Vol. 177(8). - P. 787-799.
Buchynska L.G., Brieieva O.V. Sensitivity to 4-hydroxyestradiol and DNA repair efficiency in peripheral blood lymphocytes of endometrial cancer patients // Exp. Oncol. - 2018. -Vol. 40(1). - P. 68-72.
Берштейн Л.М., Порошина Т.Е., Коваленко И.М., Васильев Д.А. Сравнение уровня маркера повреждения ДНК 8-гидрокси-2>-дезоксигуанозина в сыворотке крови больных раком молочной железы и эндометрия, страдающих или не страдающих сахарным диабетом // Бюлл экспер биол мед. - 2016. - Т. 161(4). - С. 539-542.
Ethier J.L., Desautels D.N., Templeton A.J. et al. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis // Gynecol. Oncol. - 2017. - Vol. 145(3). - P. 584-594.
Verdoodt F., Kjaer S.K., Friis S. Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: Summary of epidemiologic evidence of cancer risk and prognosis.
Takiuchi T., Blake E.A., Matsuo K. et al. Aspirin use and endometrial cancer risk and survival // Gynecol. Oncol. -2018. - Vol. 148(1). - P. 222-232.
Berstein L.M., Imyanitov E.N., Suspitsin E.N. et al. CYP19 gene polymorphism in endometrial cancer patients // J. Cancer Res. Clin. Oncol. - 2001. - Vol. 127(2). - P. 135-138.
Stelloo E., Jansen A.M.L, Osse E.M. et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer // Ann. Oncol. - 2017. - Vol. 28(1). - P. 96-102.
Берштейн Л.М., Порошина Т.Е., Васильев Д.А. Адипокины, миокины и цитокины при раке эндометрия: связь с фенотипом избыточной массы тела и клиникоморфологическими особенностями опухоли // Ожирение и метаболизм. - 2017. - Т. 14(1). - С. 35-40.
Hofheinz K., Kakularam K.R., Adel S. et al. Conversion of proinflammatory murine Alox5 into an anti-inflammatory 15s-lipoxygenating enzyme by multiple mutations of sequence determinants // Arch Biochem Biophys. -2013. - Vol. 530(1). - P. 40-47.
Stachowska E., Dziedziejko V., Safranow K. et al. Effect of conjugated linoleic acids on the activity and mRNA expression of 5- and 15-lipoxygenases in human macrophages // J. Agric. Food. Chem. - 2007. - Vol. 55(13). - P. 5335-5342.
Берштейн Л.М., Иевлева А.Г., Порошина Т.Е., Коваленко И.М. Сравнительные особенности больных раком эндометрия со «стандартным» и «метаболически здоровым» ожирением: генетический и генотоксический аспект // Вопр. онкол. - 2017. - Т 63(1). - С. 69-75.
Cawthon R.M. Telomere measurement by quantitative PCR // Nucleic. Acids Res. - 2002. - Vol. 30(10). - e47.
O'Connell J., Lynch L., Hogan A. et al. Preadipocyte factor-1 is associated with metabolic profile in severe obesity // J. Clin. Endocrinol. Metab. - 2011. - Vol. 96(4). - E680-84.
Sliwicka E., Cison T., Kasprzak Z., Nowak A., Pilaczyska-Szczesniak T. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing // pLoS One. - 2017. - Vol. 12(7). - e0181259.
Murali R., Soslow R.A., Weigelt B. Classification of endometrial carcinoma: more than two types // Lancet Oncol. - 2014. - Vol. 15(7). - e268-278.
Bosse T., Nout R.A., McAlpine J.N. et al. Molecular Classification of Grade Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups // Am. J. Surg. Pathol. - 2018. - Vol. 42(5). - P. 561-568.
Haruma T., Nagasaka T., Nakamura K. et al. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability // PLoS One. - 2018. - Vol. 13(4) - e0195655.
Bellone S., Bignotti E., Lonardi S. et al. Polymerase e (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro // Gynecol. Oncol. - 2017. - Vol. 144(1). - P. 146-152.
Berstein L.M. Macrosomy. - Obesity and Cancer, 1997, Nova Science Publ., NY - 195pp.
Felix A.S., Brinton L.A. Cancer Progress and Priorities: Uterine Cancer // Cancer Epidemiol Biomarkers Prev. - 2018. - Vol. 27(9). - P. 985-994.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019